Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of “Buy” by Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) has been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $122.20.

A number of equities research analysts have recently commented on the stock. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 11th. Mizuho boosted their target price on Lantheus from $115.00 to $125.00 in a report on Friday, May 5th. JMP Securities increased their price target on Lantheus from $120.00 to $130.00 in a report on Friday, May 5th. Truist Financial boosted their price objective on shares of Lantheus from $115.00 to $125.00 in a report on Friday, May 5th. Finally, SVB Securities increased their target price on shares of Lantheus from $120.00 to $127.00 in a research note on Friday, May 5th.

Lantheus Trading Up 0.0 %

Shares of Lantheus stock opened at $96.29 on Thursday. The company has a current ratio of 2.80, a quick ratio of 2.65 and a debt-to-equity ratio of 1.25. Lantheus has a twelve month low of $47.46 and a twelve month high of $100.85. The firm has a market capitalization of $6.58 billion, a PE ratio of -310.61 and a beta of 0.66. The firm’s 50-day moving average price is $88.10 and its 200 day moving average price is $68.69.

Lantheus (NASDAQ:LNTH – Get Rating) last released its earnings results on Thursday, May 4th. The medical equipment provider reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.16. Lantheus had a positive return on equity of 58.60% and a negative net margin of 1.72%. The business had revenue of $300.78 million for the quarter, compared to the consensus estimate of $280.65 million. On average, sell-side analysts predict that Lantheus will post 5.2 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other news, CEO Mary Anne Heino sold 82,055 shares of the company’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $73.00, for a total transaction of $5,990,015.00. Following the sale, the chief executive officer now owns 741,650 shares of the company’s stock, valued at $54,140,450. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CAO Andrea Sabens sold 386 shares of Lantheus stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $71.58, for a total value of $27,629.88. Following the completion of the transaction, the chief accounting officer now owns 62,290 shares in the company, valued at $4,458,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mary Anne Heino sold 82,055 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $73.00, for a total transaction of $5,990,015.00. Following the transaction, the chief executive officer now owns 741,650 shares of the company’s stock, valued at approximately $54,140,450. The disclosure for this sale can be found here. Insiders sold 253,903 shares of company stock valued at $19,639,815 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently modified their holdings of LNTH. Toroso Investments LLC purchased a new position in Lantheus in the first quarter valued at $645,000. Ameriprise Financial Inc. increased its holdings in shares of Lantheus by 15.0% in the 1st quarter. Ameriprise Financial Inc. now owns 222,136 shares of the medical equipment provider’s stock valued at $18,340,000 after acquiring an additional 29,033 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Lantheus by 4.4% during the 1st quarter. JPMorgan Chase & Co. now owns 340,028 shares of the medical equipment provider’s stock worth $28,072,000 after acquiring an additional 14,244 shares in the last quarter. Centaurus Financial Inc. lifted its stake in Lantheus by 14.2% during the first quarter. Centaurus Financial Inc. now owns 23,519 shares of the medical equipment provider’s stock worth $1,942,000 after purchasing an additional 2,927 shares during the last quarter. Finally, Colony Group LLC boosted its holdings in Lantheus by 99.1% in the first quarter. Colony Group LLC now owns 114,237 shares of the medical equipment provider’s stock valued at $9,431,000 after purchasing an additional 56,861 shares in the last quarter. 97.62% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.